Renal cell carcinoma

This early-stage trial is testing an experimental therapy called HS-IT101 for people with advanced clear cell renal cell carcinoma, a type of kidney cancer. The treatment involves collecting immune cells from the patient's tumor, multiplying them in the lab, and infusing them bac…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

Researchers are testing two drugs, toripalimab and axitinib, in adults with advanced non-clear cell kidney cancer or renal medullary carcinoma who have not received prior treatment and still have their primary kidney tumor. Everyone receives the drugs for about 12 weeks. Then a t…

This phase 2 trial tests a combination of two drugs, envafolimab and lenvatinib, as a first treatment for people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 participants and measure how well the drugs shrink liver tumors. It is not yet rec…

This phase II trial is testing whether giving toripalimab (an immunotherapy) plus axitinib (a targeted therapy) for about 12 weeks before a possible delayed kidney removal can help control advanced clear cell kidney cancer. The study enrolls adults whose primary kidney tumor is s…

This trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney canc…

This trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…

This phase II trial tests a combination of two immunotherapies (ipilimumab and sintilimab) plus a targeted drug (lenvatinib) as a first treatment for people with a rare and aggressive form of kidney cancer called TFE3-rearranged renal cell carcinoma. The study enrolls about 66 pa…

This phase III trial compares the immunotherapy drug pembrolizumab to active surveillance (no treatment) after kidney cancer surgery in patients with non-clear cell renal cell carcinoma, a less common type of kidney cancer. The goal is to see if pembrolizumab can help the immune …

This early-stage trial tests whether a personalized vaccine, made from each patient's unique tumor mutations, can safely boost the effects of the immunotherapy drug pembrolizumab in people with advanced kidney cancer. The vaccine is designed to train the immune system to recogniz…

This study tests whether giving focused radiation or surgery to all visible tumors (both the original kidney tumor and its metastases) can allow people with advanced kidney cancer to stop all cancer treatments for at least a year. Participants must have stable or partially improv…

This Phase 2 trial tests whether giving two drugs (anlotinib and benmelstobart) before surgery can improve outcomes for people with localized kidney cancer. About 144 participants will either receive the drug combo followed by partial nephrectomy, or surgery alone. The main goal …

This study tests whether adding the cholesterol drug atorvastatin to standard targeted therapy (axitinib) and immunotherapy (toripalimab) can help people with advanced kidney cancer who are not responding well to treatment. The drug combination is guided by lab tests on patient-d…

This study tests whether giving a combination of two drugs (a PD-L1 inhibitor called TQB2450 and anlotinib) before surgery can shrink complex kidney tumors enough to allow surgeons to remove only the tumor and save the rest of the kidney. About 33 adults with advanced clear cell …

This study tests whether giving a combination of three drugs (pembrolizumab, belzutifan, and lenvatinib) before surgery can shrink kidney tumors in people with localized clear cell renal cell carcinoma. About 150 participants will receive the drugs for 12 weeks before surgery, th…

This phase 2 trial tests whether adding a probiotic capsule (MO-03) to the drug zanzalintinib can help treat metastatic kidney cancer that has worsened after immunotherapy. About 34 adults with advanced clear cell renal cell carcinoma will receive both treatments. The goal is to …

This early-phase study tests a new drug combination (L19IL2 plus ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 partici…

This Phase 1 trial tests a new drug called HLX05-N, which is a biosimilar (a copy) of the cancer drug Erbitux, in 387 people with metastatic colorectal cancer. Participants will receive either HLX05-N or Erbitux (from the US or EU) along with standard chemotherapy. The study aims…

This study tests whether adding a 5-day fasting-mimicking diet (low-calorie, low-protein) to the usual combination of toripalimab (an immunotherapy) and axitinib (a targeted drug) can help people with advanced kidney cancer. The trial will enroll 43 adults who have not had prior …

This early study tests a new cell therapy called UCL70805F in 21 people with advanced clear cell kidney cancer that has not responded to standard treatments. The therapy uses immune cells designed to target a protein called CD70 on cancer cells. The main goals are to check safety…

This phase 2 study tests whether adding an immunotherapy drug (iparomlimab and tuvonralimab) and targeted radiation to a standard targeted therapy (fruquintinib) can help people with metastatic colorectal cancer that has spread to a few spots. The trial will enroll 60 adults who …

This study tests a new drug called WGI-0301 combined with the immunotherapy nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe and can shrink tumors. About 230 adults aged 18 to 75 will take part, and the study does not use a p…

This study tests if temporarily restricting blood flow to an arm (called ischemic preconditioning) before kidney cancer surgery can reduce kidney damage. About 174 adults having partial nephrectomy will be randomly assigned to receive this technique or standard care. The goal is …

This phase 2 trial will test a combination of precise radiation (SBRT) and two drugs—anlotinib (which cuts off tumor blood supply) and bemarituzumab (which boosts the immune system)—in 27 people with advanced kidney cancer that cannot be surgically removed. The main goal is to se…

This study watches 226 adults with small kidney tumors (stage T1a) who get radiofrequency ablation, a treatment that uses heat to destroy cancer cells. Researchers will track how well the procedure works and any side effects. No extra treatments or tests are given—just normal car…

This study tests whether combining two drugs, pembrolizumab and lenvatinib, can help people with advanced kidney cancer (clear cell type) whose cancer returned after prior immunotherapy. About 108 adults will receive the combination to see if it shrinks tumors or delays cancer gr…

This phase 3 trial tests a radioactive drug called Lu-177 PSMA in 20 people with metastatic clear cell kidney cancer that has worsened after at least two prior treatments. The drug is designed to seek out and destroy cancer cells while limiting damage to healthy tissue. Researche…

This study tests a new drug combination (SHR-1811 plus bevacizumab) as a second-line treatment for people with metastatic colorectal cancer that has worsened after initial therapy. About 80 adults aged 18-75 will participate. The goal is to see if the combo shrinks tumors and del…

This study tests a highly precise type of radiation called SBRT for people with kidney cancer who cannot undergo surgery. The treatment uses a robotic system (CyberKnife) to deliver high-dose radiation directly to the tumor while sparing healthy tissue. Researchers will track 60 …

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib or axitinib) in 36 adults with advanced clear cell kidney cancer that has worsened after initial treatment. The main goal is to see if the combination can …

This clinical trial is for adults with metastatic clear cell kidney cancer. It compares having surgery to remove the kidney tumor either before or after starting immunotherapy drugs (ipilimumab and nivolumab). The goal is to see which timing helps people live longer without the c…

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This phase 2 trial tests a combination of RP2 (a modified herpes simplex virus that targets and destroys tumor cells) and tivozanib (a drug that blocks tumor blood vessel growth) in 35 patients with metastatic kidney cancer that worsened after immunotherapy. The goal is to see if…

This phase 3 trial tests whether a combination of two drugs, vorolanib and everolimus, can help people with advanced kidney cancer whose disease has worsened after immunotherapy. About 116 participants will be randomly assigned to receive either the combo or the standard drug sun…

This study tests a combination of two drugs—envafolimab (an immunotherapy injection) and axitinib (a targeted therapy pill)—as a first treatment for people with advanced kidney cancer that has spread or cannot be removed. About 30 participants will receive the treatment for up to…

This early-stage trial tests an experimental imaging agent called 68Ga-NYM096 in 20 adults who have a kidney mass of uncertain nature seen on CT or MRI and are scheduled for surgery. The agent is designed to attach to a protein common on clear cell renal cell carcinoma cells, pot…

This study tests whether a special PET scan using a drug called 89Zr-girentuximab can detect kidney cancer that remains or comes back after initial treatment. Ten adults with clear cell renal cell carcinoma will receive the drug and then have a PET scan. Some will also have a sec…

This study looks for protein markers in urine and blood that could help identify different types of kidney cancer without needing a biopsy. Researchers will analyze stored urine samples from 300 people and collect blood before and after kidney removal surgery. The goal is to deve…

This study tests whether a special PET scan using 82-Rb can tell how aggressive a kidney tumor is. Doctors will compare the scan results to the actual tumor grade after surgery. If it works, patients might avoid unnecessary biopsies or surgeries. The study involves 50 adults with…

This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…

This study tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) can prevent postoperative delirium in elderly patients undergoing urological surgery. Researchers will apply TMS to the left frontal lobe during anesthesia and monit…

This trial tests whether an ultrasound-guided nerve block called QLESP can reduce pain and the need for opioid painkillers after robot-assisted partial nephrectomy for kidney cancer. Adults scheduled for this surgery are randomly assigned to receive either the QLESP block or a st…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This pilot study tests whether the experimental drug casdatifan can alter the activity of genes controlled by HIF-2α in people with advanced clear cell kidney cancer that has stopped responding to prior treatments. Participants take casdatifan daily, and researchers analyze tumor…

This study planned to test whether kidneys with small, low-risk tumors could be removed from donors, have the tumor taken out, and then be transplanted into patients with kidney failure. The goal was to increase the number of available donor kidneys. However, the study was withdr…

This study looks at kidney cancer tumors that have multiple small nodules inside them. Researchers will take samples from 10 patients and use advanced gene mapping to see if the nodules are different. They will also grow tiny 3D tumor models in the lab to test how they respond to…

This study looks at 860 Chinese patients with advanced kidney cancer to see which order of treatments works better: starting with one drug combo and switching to another, or the reverse. The goal is to find the best sequence to help patients live longer and feel better. Participa…